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Abstract
Objectives
The development of hyperglycemia and the use of early parenteral feeding are associated with poor outcomes
in critically ill patients. We therefore examined the impact of exogenous glucose administration on the
integrated metabolic function of endotoxemic mice using our recently developed frequently sampled
intravenous glucose tolerance test (FSIVGTT). We next extended our findings using a cecal ligation and
puncture (CLP) sepsis model administered early parenteral glucose support.
Methods
Male C57BL/6J mice, 8-12 weeks, were instrumented with chronic indwelling arterial and venous catheters.
Endotoxemia was initiated with intra-arterial lipopolysaccharide (LPS; 1 mg/kg) in the presence of saline or
glucose infusion (100 µL/hr), and an FSIVGTT was performed after five hours. In a second experiment,
catheterized mice underwent CLP and the impact of early parenteral glucose administration on glucose
homeostasis and mortality was assessed over 24 hrs.
Measurements
And MAIN RESULTS: Administration of LPS alone did not impair metabolic function, whereas glucose
administration alone induced an insulin sensitive state. In contrast, LPS and glucose combined caused marked
glucose intolerance and insulin resistance and significantly impaired pancreatic insulin secretion. Similarly,
CLP mice receiving parenteral glucose developed fulminant hyperglycemia within 18 hrs (all > 600 mg/dl)
associated with increased systemic cytokine release and 40% mortality, whereas CLP alone (85 ± 2 mg/dL) or
sham mice receiving parenteral glucose (113 ± 3 mg/dL) all survived and were not hyperglycemic. Despite
profound hyperglycemia, plasma insulin in the CLP glucose-infused mice (3.7 ± 1.2 ng/ml) was not higher
than sham glucose infused mice (2.1 ± 0.3 ng/ml).
Conclusions
The combination of parenteral glucose support and the systemic inflammatory response in the acute phase of
sepsis induces profound insulin resistance and impairs compensatory pancreatic insulin secretion, leading to
the development of fulminant hyperglycemia.
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Abstract
Objectives: The development of hyperglycemia and the use of early parenteral feeding are associated with poor
outcomes in critically ill patients. We therefore examined the impact of exogenous glucose administration on the
integrated metabolic function of endotoxemic mice using our recently developed frequently sampled intravenous
glucose tolerance test (FSIVGTT). We next extended our findings using a cecal ligation and puncture (CLP) sepsis
model administered early parenteral glucose support.
Methods: Male C57BL/6J mice, 8-12 weeks, were instrumented with chronic indwelling arterial and venous
catheters. Endotoxemia was initiated with intra-arterial lipopolysaccharide (LPS; 1 mg/kg) in the presence of saline or
glucose infusion (100 µL/hr), and an FSIVGTT was performed after five hours. In a second experiment, catheterized
mice underwent CLP and the impact of early parenteral glucose administration on glucose homeostasis and mortality
was assessed over 24 hrs.
Measurements: And MAIN RESULTS: Administration of LPS alone did not impair metabolic function, whereas
glucose administration alone induced an insulin sensitive state. In contrast, LPS and glucose combined caused
marked glucose intolerance and insulin resistance and significantly impaired pancreatic insulin secretion. Similarly,
CLP mice receiving parenteral glucose developed fulminant hyperglycemia within 18 hrs (all > 600 mg/dl) associated
with increased systemic cytokine release and 40% mortality, whereas CLP alone (85 ± 2 mg/dL) or sham mice
receiving parenteral glucose (113 ± 3 mg/dL) all survived and were not hyperglycemic. Despite profound
hyperglycemia, plasma insulin in the CLP glucose-infused mice (3.7 ± 1.2 ng/ml) was not higher than sham glucose
infused mice (2.1 ± 0.3 ng/ml).
Conclusions: The combination of parenteral glucose support and the systemic inflammatory response in the acute
phase of sepsis induces profound insulin resistance and impairs compensatory pancreatic insulin secretion, leading
to the development of fulminant hyperglycemia.
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Introduction
Sepsis is a devastating public health problem killing nearly
300,000 people in the U.S. each year [1]. Hyperglycemia
frequently complicates this illness imparting a worse prognosis
when it develops [2,3]. Optimal regulation of blood glucose in
the clinical setting is controversial as several carefully
performed large trials have led to mixed conclusions possibly
related to differences in patient population, nutritional support,
general care protocols, monitoring techniques, and, most
importantly, glucose control targets [2,4–8]. What is clear is
that hyperglycemia in critical illness portends poor outcome.
However, the appropriate level of glucose control remains
controversial. Further complicating the issue of glucose
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homeostasis in critical illness, parenteral nutritional support has
been linked to the development of hyperglycemia in critically ill
patients [9], and more recently, its early initiation has been
associated with increased infection rates, duration of
mechanical ventilation, duration of renal replacement therapy,
hospital length of stay, and incremental health care costs [8].
Although multiple systems have been implicated in the
development of hyperglycemia in critical illness, the basic
underlying mechanisms remain poorly understood [10,11]. In
addition, the mechanistic relationship between early parenteral
nutritional support and adverse outcomes has not been
explored. It is generally accepted that hepatic gluconeogenesis
is increased and that liver and skeletal muscle become insulin
resistant in the septic state [10]. However, our recent data
suggest that pancreatic insulin production in response to
hyperglycemia may be a key determinant of survival in animal
models of sepsis [12]. In contrast to the common clinical
observation of hyperglycemia in critically ill adult patients,
healthy humans do not become hyperglycemic after exposure
to endotoxin, and they demonstrate preserved insulin
sensitivity [13–15] suggesting that comorbidities or a
combination of insults are required to drive metabolic
decompensation in critically ill patients. Similarly, the absence
of hyperglycemia is characteristic of multiple animal models of
sepsis [12,16–19], and the data presented herein suggest that
insulin sensitivity is preserved in endotoxemic mice in the
absence of glucose supplementation.
A better understanding of the pathways driving
hyperglycemia in the critically ill may allow for the development
of novel therapies targeting the mechanisms of metabolic
dysfunction rather than the consequences thereof, thus
improving outcome while limiting potentially severe adverse
effects such as hypoglycemia. We propose that an interaction
between circulating glucose and the systemic inflammatory
response syndrome propagates hyperglycemia by inducing
pancreatic dysfunction in combination with profound insulin
resistance in peripheral metabolic tissues.
We recently published the application of the frequently
sampled intravenous glucose tolerance test (FSIVGTT) in
conscious mice, allowing for the first time an integrated
characterization of glucose disposal and concomitant
pancreatic function [20]. In addition, we previously reported the
observations that hyperglycemia alone is necessary but not
sufficient to account for mortality in endotoxemic mice and that
profound metabolic dysregulation and death occur when the
pancreatic response to hyperglycemia is impaired [12]. We
designed the current study to further interrogate glucose and
insulin metabolism in endotoxemic mice using the novel
FSIVGTT. We examine the hypothesis that circulating glucose
and the systemic inflammatory response syndrome combine to
drive a cycle of metabolic dysfunction and hyperglycemia in
early sepsis, which may contribute to adverse outcome in the
setting of early nutritional support. Our results demonstrate that
insulin sensitivity is preserved in endotoxemic mice and in mice
exposed to exogenous glucose alone, while profound insulin
resistance develops in mice exposed to endotoxin in the setting
of glucose supplementation. In addition to effects on insulin
sensitivity, combined exposure to glucose supplementation and
an inflammatory stimulus also impairs pancreatic insulin
secretion thereby worsening metabolic dysfunction. Finally, we
extend these findings into a clinically relevant sepsis model,
cecal ligation and puncture (CLP).
Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. Animal
protocols were approved by the Institutional Animal Care and
Use Committee at the University of Pittsburgh (Protocol
Number: 1106265).
In vivo endotoxemia
Male C57BL/6J mice (20–25 g, 8–12 wks old) underwent
surgical insertion of indwelling femoral arterial and venous
catheters as previously described [12,21]. In brief, mice were
anesthetized with inhaled isoflurane (2%) for insertion of micro-
renathane catheters (MRE-025; Braintree Scientific, Braintree,
MA) into the left femoral artery and vein. Catheters were
sutured in place, stabilized with surgical grade tissue glue,
tunneled subcutaneously to exit the skin at the upper back,
taped to a wire attached to posterior cervical muscles for
stiffness (792500; A-M Systems, Sequim, WA), and connected
to a 360° dual channel swivel designed for mice (375/D/22QM;
Instech, Plymouth Meeting, PA). Catheter patency was
maintained by continuous sterile infusion of 7 µL/h saline
containing 20 units/mL heparin (APP Pharmaceuticals, Melrose
Park, IL) using a syringe pump with multisyringe adaptor (R99-
EM; Razel Scientific Instruments, Stamford, CT). Pulsatile
blood pressure was monitored continuously, recorded, and
stored for off-line analysis, using Windaq Acquisition software
(v 2.34, Akron, OH). After three days recovery from surgery,
mice began continuous infusions of saline (100 µL/hr) or
glucose (100 µL/hr; 50% Dextrose (D50) targeting
approximately 40% of daily calorie requirements [21]). Mice
had free access to water and chow until five hours prior to the
frequently sampled intravenous glucose tolerance test
(FSIVGTT). Oral intake was restricted prior to performance of
the FSIVGTT as is standard practice prior to detailed metabolic
assessment [22]. Endotoxemia was induced 24 hours after
infusion initiation by an intra-arterial bolus of bacterial
lipopolysaccharide (LPS, 1 mg/kg, E. Coli 055:B5 Sigma,
Figure 1A) [12]. We chose endotoxemia as a model for sepsis
in order to allow for tight control of experimental variables given
the complexity of the preparation using chronic double
catheterization and the FSIVGTT. We infused glucose for 24
hours prior to inflammatory stimulus in order to maintain
consistency with our previously published model [12]. To define
the metabolic response of these animals including both
peripheral glucose utilization and pancreatic function, FSIVGTT
was performed as previously described [20] five hours after
LPS infusion (Figure 1A). Briefly, an intravenous (iv) glucose
bolus of 1 g/kg D50 was given over approximately 15 sec.
Arterial blood was sampled for glucose (~2 µL; glucometer)
and insulin (~20 µL; radioimmunoassay) at -30, -10, 0, 1, 2, 4,
Hyperglycemia and Endogenous Insulin in Sepsis
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8, 12, 16, 20, 30, 6, 90, and 120 min with additional glucose
determinations at 3, 5, 6, 10, 14, 18, 25, 40, and 50 min (Figure
1A). Red blood cells were spun down and re-infused into the
mouse throughout the protocol to avoid anemia. Heart rate and
arterial blood pressure were monitored continuously throughout
the FSIVGTT protocol to ensure that the animals were not
hypovolemic and maintained stable cardiovascular function.
Animals were sacrificed upon termination of the FSIVGTT
(t=7hrs) by pentobarbital overdose and exsanguination,
according to American Veterinary Medical Association
guidelines for euthanasia.
Mathematical modeling
Insulin and glucose data were entered into a Minimal Model
[23] adapted for the faster glucose kinetics seen in conscious
mice compared to humans [20]. The Minimal Model provides
several key assessments of metabolic function including
glucose tolerance (area under the glucose curve, AUCg),
Figure 1.  Experimental timelines.  (A) Chronically catheterized mice (femoral artery and vein) were given three days to recover
from surgery and infused intravenously (iv) with either saline or glucose for 24 hours prior to intra-arterial administration of either
lipopolysaccharide (LPS; 1 mg/kg) or vehicle. Five hours after LPS or vehicle administration a frequently sampled intravenous
glucose tolerance test (FSIVGTT) was performed over a two hour period. An iv glucose bolus of 1 g/kg D50 was given over
approximately 15 sec (▲). Subsequently, multiple samples of either blood glucose and plasma insulin (Δ) or glucose alone (↑) were
taken from the arterial catheter at the times identified. Red blood cells were spun down and re-infused into the mouse throughout
the protocol to avoid anemia. (B) Mice underwent cecal ligation and puncture (CLP) immediately after chronic catheterization of the
femoral artery and vein. Animals were infused intravenously with either saline or glucose upon completion of surgery and followed
for 24 hrs. Blood glucose and plasma insulin (Δ) or blood glucose alone (↑) were sampled from the arterial catheter at the times
identified.
doi: 10.1371/journal.pone.0067716.g001
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insulin sensitivity (SI), glucose effectiveness (a measure of non-
insulin mediated glucose uptake, Sg), acute insulin response to
glucose (an in vivo assessment of pancreatic beta cell function,
AIRg), and the Disposition Index (= SI x AIRg), an integrated
index of the relationship between insulin sensitivity of the
peripheral tissues and compensatory responsiveness of the
pancreas (a low disposition index is highly predictive of
progression to type 2 diabetes) [23]. Taken together, these
parameters provide an integrated in vivo assessment of
glucose handling and insulin secretion in endotoxemic mice.
Cecal ligation and puncture
Male C57BL/6J mice (20–25 g, 8–12 wks old) underwent
surgical insertion of indwelling femoral arterial and venous
catheters as previously described [12]. Immediately following
catheter placement, laparotomy was performed and the cecum
mobilized. A ligature (3-0 silk) was placed around the proximal
25% of the cecum and tightly secured. A single puncture of the
proximal cecum was made with a 16 gauge needle. Fecal
matter was expressed by gently squeezing the proximal cecum
between the thumb and forefinger, and then abdominal fascia
was approximated and the wound closed with surgical grade
tissue glue. Control mice underwent sham surgery consisting of
laparotomy with manipulation of the cecum and abdominal
closure. Immediately post operatively, continuous infusions of
saline (100 µL/hr, n=9) or glucose (D50, 100µL/hr, n=10) were
initiated (Figure 1B). Oral intake was restricted post-operatively
in sham-operated mice in order to control for the absence of
oral intake in mice undergoing CLP. Blood pressure and heart
rate were monitored continuously, recorded, and stored for off-
line analysis using Windaq Acquisition software (v 2.34, Akron,
OH). 18 hrs following CLP, blood was sampled from the arterial
catheter for insulin, glucose, and cytokine determination as
previously described [12]. Surviving animals were sacrificed at
24 hrs. Upon sacrifice, serial dilutions of whole blood were
plated, incubated at 37oC for 24 hr, and bacterial colonies
counted. FSIVGTT was not performed in CLP mice.
Biochemical Assays
Blood glucose was measured using a Prodigy Autocode
glucometer (~1 µL whole blood; Diagnostic Devices, Charlotte,
NC). Plasma insulin was measured by radioimmunoassay
(5 µL; Linco sensitive rat insulin RIA kit; Millipore, Billerica,
MA). Inflammatory cytokines were measured in mouse plasma
(5x dilution) using the Bio-Plex Pro mouse cytokine 23-plex
assay according to manufacturer instructions (Product #
M60-009RDPD, Bio-Rad Laboratories, Hercules, CA).
Statistics
Data are presented as mean ± standard error of the mean
(SEM) unless otherwise indicated. Differences between groups
were assessed by one-way or two-way ANOVA where
appropriate with post-hoc Bonferroni tests and were considered
statistically different for p<0.05. Cytokine data were log
transformed for normalization where appropriate prior to
statistical analysis. Nonparametric data were analyzed by the
Kruskal Wallis test with post-hoc Wilcoxon rank sum tests
corrected for multiple comparisons using the Bonferroni
method (StataSE v 12.1, StataCorp, College Station, TX).
Glucose measurements above the limit of glucometer detection
were assigned a value of 600 mg/dL for the purposes of
analysis.
Results
A total of 30 mice were catheterized for the endotoxemia
study. Experimental groups received saline (Sal) or glucose
(Glu) infusion for 24 hrs prior to intra-arterial administration of
vehicle or LPS (Veh Sal [n=7], Veh Glu [n=7], LPS Sal [n=8],
and LPS Glu [n=8], Figure 1). Five hours after LPS, the
FSIVGTT was performed over two hours with saline and
glucose infusions maintained throughout (Figure 1). Mice in
each of the four experimental groups were of similar weight
prior to intervention (Figure 2A). As expected, glucose infused
mice consumed fewer calories than their saline infused
counterparts (Figure 2B).
Baseline blood glucose and plasma insulin were assessed
immediately prior to the FSIVGTT (t=-30 min on Figure 1).
Glucose infusion produced a mild hyperglycemia (141 ± 9 mg/
dl), whereas LPS administration tended to lower blood glucose
during saline infusion (83 ± 5 mg/dl) and raise blood glucose
during glucose infusion (169 ± 17 mg/dl) such that baseline
blood glucose in the LPS Glu group was double that in the LPS
Sal group (Figure 2C 3rd vs. 4th bar, p<0.0001). Baseline
plasma insulin followed a similar qualitative pattern as the
blood glucose, but insulin levels were 10-fold higher in the LPS
Glu group compared to the LPS Sal group (2.30 ± 0.47 vs. 0.22
± 0.03, Figure 2D, 3rd vs. 4th bar, p<0.0001). These data were
consistent with our previously published data [12].
Prior to initiation of and 24 hours into saline or glucose
infusion, blood pressure was not different across all study
groups (Figure 3). LPS administration induced a drop in blood
pressure of approximately 20 mmHg, independent of whether
animals were receiving Sal or Glu infusion (Figure 3). Over the
two-hour multiple blood sampling period of the FSIVGTT, blood
pressure drifted downwards approximately 5-10 mmHg, but did
not reach a hypotensive threshold (60 mmHg). The difference
in blood pressure between the Veh and LPS groups was
maintained through end of the FSIVGTT and remained
independent of saline or glucose infusion (Figure 3).
The combination of endotoxemia and glucose infusion
induces profound glucose intolerance
The glucose disposal and insulin secretion curves for the
four experimental groups undergoing FSIVGTT are shown in
Figure 4 A–D. Glucose tolerance, defined by area under the
glucose disposal curve, was not different between the Veh and
LPS groups administered Sal (Figure 4A and Figure 5A, open
and solid diamonds). During Glu infusion in the absence of LPS
(Figure 4B open triangles), the blood glucose peaked higher
than for either of the Sal-infused groups (503±32 [Veh Glu]
versus 413±19 [Veh Sal] or 411±16 [LPS Sal] mg/dL,
p<0.0001; Figure 4), but due to rapid disposal the glucose
tolerance was not different than either of the Sal-infused
groups (Figure 5A). Importantly, when LPS was administered in
the presence of glucose (LPS Glu), glucose peaked at similar
Hyperglycemia and Endogenous Insulin in Sepsis
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levels to the Veh Glu group (567±9 [LPS Glu] mg/dL), but
glucose disposal was markedly impaired (Figure 4B and Figure
5A solid triangles). Thus, whereas we demonstrate a distinct
lack of impairment of glucose disposal in response to glucose
infusion or endotoxin alone, mice exposed to the combination
of LPS and Glu experience profound glucose intolerance.
The combination of endotoxemia and glucose infusion
induces marked insulin resistance and impairs first
phase insulin secretion
During saline infusion, the peak insulin secretion was
comparable between the Veh Sal (29.8±10.5 ng/ml) and LPS
Sal (30.2±5.9 ng/ml) groups (Figure 4C, open and closed
diamonds). Although the decay curve for insulin appeared
slightly slower for the LPS Sal group than the Veh Sal group,
Figure 2.  Physiological variables.  Mean ± SEM for (A) body weight, (B) food intake over 24 hrs prior to lipopolysaccharide (LPS;
1 mg/kg) administration (note: glucose infused mice consumed fewer calories as the glucose accounted for approximately 40% of
their daily calorie intake), (C) pre-FSIVGTT blood glucose, and (D) plasma insulin 5 hrs after either LPS or vehicle (Veh)
administration in mice infused with either saline (Sal) or glucose (Glu) at 100 µL/hr for 29 hrs. Statistical differences were
determined by two-way ANOVA with differences between individual means determined by post-hoc Bonferroni tests.
doi: 10.1371/journal.pone.0067716.g002
Hyperglycemia and Endogenous Insulin in Sepsis
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the AIRg were not significantly different (Figure 5C open versus
closed diamonds). Similarly, the modeled levels of Si and DI
were not different between the saline-infused vehicle and LPS
groups (Figure 5B and 5D open and closed diamonds). In both
glucose-infused groups, the peak insulin secretion (13.4 ± 2.0
[Veh Glu] and 8.8 ± 1.1 [LPS Glu] ng/mL) was significantly
reduced compared to the two saline-infused groups (p = 0.002;
Figure 4D). Similarly, the AIRg was significantly less in the
glucose-infused compared to saline-infused groups (Figure 5C
triangles versus diamonds). The decreased insulin secretion of
the Veh Glu group was metabolically appropriate given that a
normal DI was maintained by virtue of the development of an
insulin sensitive state (Figure 5B and 5D open triangles).
However, when LPS was administered in the presence of
glucose, the low AIRg was not due to increased sensitivity to
insulin; in fact, modeled Si was reduced in the LPS Glu group
(Figure 5B closed triangles). The dual metabolic insult of
simultaneously reduced Si and AIRg resulted in a DI that was
several-fold reduced compared to either the Veh Glu or LPS
Sal experimental groups (Figure 5D closed triangles).
There was no evidence that Sg, non-insulin-mediated
glucose uptake, was impacted by endotoxemia, glucose
administration, or the combination. The Sg in the Veh Sal
(0.161 ± 0.037 1/min), LPS Sal (0.093 ± 0.015 1/min), Veh Glu
(0.117 ± 0.009 1/min), and LPS Glu (0.140 ± 0.018 1/min)
groups were not significantly different from each other. Thus,
the changes in glucose disposal that we report are dependent
on endogenous insulin secretion and its effect on metabolically
active tissue.
Figure 3.  Hemodynamic profiles before and after intra-arterial endotoxin.  Change in mean arterial blood pressure over time in
four groups of animals receiving either (1) intra-venous saline infusion and vehicle (Veh Sal), (2) intra-venous saline infusion intra-
arterial lipopolysaccharide (1 mg/kg, LPS Sal), (3) intra-venous glucose infusion and vehicle (Veh Glu), (4) intra-venous glucose
infusion and LPS (1 mg/kg, LPS Glu). Time scale is adjusted to indicate effects of intra-venous saline and glucose infusion, LPS
administration, and the frequently sampled intravenous glucose tolerance test (FSIVGTT).
doi: 10.1371/journal.pone.0067716.g003
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In summary, mice exposed to either LPS or glucose infusion
alone demonstrate normal glucose tolerance and appropriate
pancreatic responsiveness compared to control mice. In
contrast, mice exposed to LPS in the setting of glucose
supplementation exhibit profound metabolic decompensation
characterized by marked glucose intolerance, insulin
resistance, and relative pancreatic insufficiency.
The combination of parenteral glucose with cecal
ligation and puncture induces profound hyperglycemia
In order to extend the results observed in the endotoxemia
model, we employed the cecal ligation and puncture model of
sepsis in double catheterized mice. Starting body weights of
animals that underwent sham surgery followed immediately
with saline were slightly greater than sham animals receiving
glucose infusion and those undergoing cecal ligation and
puncture (30.5±1.0g [Sham Sal], 26.4±1.2g [Sham Glu],
28.2±1.6g [CLP Sal], 27.6±1.4g [CLP Glu], p<0.0002, n = 6-10
per group). All of the sham animals and CLP Sal animals
Figure 4.  Frequently sampled intravenous glucose tolerance test data.  Glucose disposal curves in response to an iv injection
of 1 g/kg D50 administered over 15 sec at time t = 0 are depicted for (A) mice receiving iv saline infusion and vehicle (Veh Sal, open
diamonds) or iv saline infusion and intra-arterial lipopolysaccharide (1 mg/kg, LPS Sal, closed diamonds) and (B) iv glucose infusion
and vehicle (Veh Glu, open triangles) or mice receiving iv glucose infusion and LPS (1 mg/kg, LPS Glu, closed triangles). The
corresponding insulin response curves are shown for (C) Veh Sal and LPS Sal and (D) Veh Glu and LPS Glu groups.
doi: 10.1371/journal.pone.0067716.g004
Hyperglycemia and Endogenous Insulin in Sepsis
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Figure 5.  Minimal model data from frequently sampled intravenous glucose tolerance test.  Data are shown for (A) glucose
tolerance (area under the glucose curve; AUCg), (B) insulin sensitivity (Si), (C) acute insulin response to glucose (AIRg), and (D)
Disposition Index (DI = Si *AIRg) for four groups of animals receiving either iv saline infusion and vehicle (Veh Sal, open diamonds),
iv saline infusion and intra-arterial lipopolysaccharide (1 mg/kg, LPS Sal, closed diamonds), iv glucose infusion and vehicle (Veh
Glu, open triangles), or iv glucose infusion and LPS (1 mg/kg, LPS Glu, closed triangles). Group medians are indicated by gray
lines. Statistical differences were determined by Kruskal-Wallis test with differences between individual means determined by post-
hoc Wilcoxon rank-sum tests corrected for multiple comparisons using the Bonferroni method.
doi: 10.1371/journal.pone.0067716.g005
Hyperglycemia and Endogenous Insulin in Sepsis
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survived to the completion of the 24 hour study (in our CLP
model, mice exhibit 75% mortality at 4 days). In contrast the
CLP Glu group exhibited 40% mortality at 24 hours; only data
from mice surviving 24 hours were included in the analyses.
Similar to the LPS experiments, the presence of sepsis rather
than saline or glucose-infusion was the dominant factor
impacting blood pressure (Figure 6C). Quantitatively, the
approximately 20 mmHg lower blood pressure in the two CLP
groups compared to the two sham groups was identical to the
blood pressure differences observed between the LPS and Veh
groups in the FSIVGTT study (Figures 3 and 6). CLP mice
exhibited similar degrees of bacteremia in the presence of
either saline or glucose infusion (Figure 6D).
In sham animals administered Glu, both blood glucose and
plasma insulin were significantly elevated compared to the
Sham Sal group (Figure 6A and 6B open diamonds and open
triangles; note that chow intake was restricted in sham mice as
CLP mice did not eat post-operatively), replicating the pattern
of baseline glucose and insulin we observed in the Veh Sal and
Veh Glu groups in the endotoxemia experiments (Figure 2).
Again similar to LPS, saline-infused mice undergoing CLP
displayed relative hypoglycemia and plasma insulin (Figure 6A
and 6B closed diamonds). Strikingly, however, every CLP
animal exhibited profound hyperglycemia (> than the 600 mg/dl
detection limit of the glucometer) within 18 hours when calories
were supplemented with parenteral glucose (note: all the mice
from the CLP Glu group not included in the analyses died
between 18 and 24 hr after surgery and all exhibited blood
glucose > 600 mg/dl at the 18 hr time point). Importantly, the
marked hyperglycemia that occurred in the CLP Glu group was
associated with plasma insulin levels similar to the Sham Glu
group, which exhibited blood glucose levels 2-3 times lower
than the CLP Glu group (219±13 mg/dL, p=0.002). Thus, the
combination of a systemic inflammatory response syndrome,
whether LPS or bacterial in origin, induces marked metabolic
dysfunction in the presence of parenteral glucose
administration.
The combination of parenteral glucose with cecal
ligation and puncture exacerbates inflammatory
cytokine production
In sham-operated mice, glucose infusion had no effect on
circulating Interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-
α, or IL-10 after 18 hrs (Figure 7 A–D). In CLP mice infused
with saline both IL-6 and IL-10 were increased compared to
either sham group (Figure 7 B,D). Glucose infusion following
CLP (CLP Glu) increased IL-6 and IL-10 compared to saline
infusion (CLP Sal, Figure 7 B,D). In addition, CLP Glu mice
demonstrated increased IL-1β, IL-6, TNF-α, and IL-10
compared to Sham Sal control mice (Figure 7 A–D). The
neutrophil chemo-attractant KC also increased across the four
experimental groups in comparable fashion to IL-6 (193±40
pg/mL [Sham Sal]; 189±34 pg/mL [Sham Glu]; 7.7±1.4 x104
pg/mL [CLP Sal]; 34.4±9.9 x104 pg/mL [CLP Glu], p<0.0001).
Discussion
Previous studies have suggested that nutritional support may
be associated with hyperglycemia in the setting of critical
illness [9,18,19]. Our study extends these prior observations to
demonstrate a novel interaction between endotoxemia and
exogenous glucose administration that results in profound
insulin resistance and glucose intolerance, and importantly
leads to a state of relative pancreatic insufficiency which we
have previously shown to be associated with poor outcome in
endotoxemic mice [12]. In contrast, neither endotoxemia nor
exogenous glucose administration alone negatively impacted
metabolic function. The metabolic impairment demonstrated
with the combination of endotoxemia and glucose
administration occurred with hemodynamics comparable to
endotoxemia alone, suggesting that metabolic dysfunction is
uncomplicated by circulatory collapse. We extend our
observations using an accepted clinically relevant rodent model
of sepsis, cecal ligation and puncture, thereby enhancing our
understanding of how hyperglycemia develops in critically ill
patients. Furthermore, our models demonstrate similar
metabolic responses that will allow future exploration of
mechanisms underlying the hyperglycemic response and
uncovering potential therapeutic targets for correcting
dysregulated metabolism in sepsis.
Our prior study focused on early metabolic changes in the
evolution of the systemic inflammatory response syndrome
using a murine model of endotoxemia. Using this model, we
found that suppression of pancreatic insulin secretion
negatively impacted glucose regulation and mortality during
mild endotoxemia [12]. In order to simultaneously measure
insulin sensitivity and insulin secretion in early sepsis we
adapted the endotoxin model to include the FSIVGTT. We
chose endotoxemia as a model for sepsis in order to allow for
tight control of experimental variables given the complexity of
the preparation using chronic double catheterization,
continuous infusion of substrates, and the FSIVGTT. We
extended our endotoxemia results using the cecal ligation and
puncture (CLP) model of sepsis, though we were unable to
perform the FSIVGTT in these animals as they exhibit profound
hyperglycemia in the setting of glucose infusion (beyond the
level of detection of our glucometer) precluding the generation
of meaningful glucose and insulin disposal curves necessary
for modeling of the FSIVGTT. The 24 hr glucose infusion
administered in our endotoxemic mice provided a combined
enteral and parenteral nutrition model. Our decision to infuse
glucose prior to endotoxemia in the FSIVGTT experiments was
based on establishing the underlying metabolic abnormalities
that occurred in our previous mortality study [12]. Although our
model could be interpreted as glucose ‘pre-conditioning,’ our
data demonstrate that glucose infused animals in fact display
heightened insulin sensitivity and an increased disposition
index, indicating these mice were not metabolically
compromised. Nevertheless, in the CLP model, infusions were
initiated immediately upon completion of the surgery rather
than 24 hr in advance as in the endotoxemia study (Figure 1B).
This is important in the context of recent human data
demonstrating worse outcomes in critically ill patients treated
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with early intravenous nutrition compared to those in whom
nutritional support was delayed and enterally administered [8].
In our CLP model, the mice did not eat and infusion of glucose
amounted to approximately 40% of the daily caloric
requirement of the mouse, similar to the 20% dextrose infusion
provided to the intervention group over the first two days in the
clinical study [8]. The glucose dysregulation observed in
response to CLP and dextrose administration coupled with our
FSIVGTT results provide physiologic insight into the
deleterious effect of early intravenous nutrition in critically ill
Figure 6.  Metabolic and hemodynamic profiles after cecal ligation and puncture.  Scatter plot of individual data sets for (A) 18
hr blood glucose, (B) 18 hr plasma insulin and (C) mean arterial blood pressure for mice that have undergone either CLP or sham
surgery and infused with iv saline (Sal) or glucose (Glu) at 100 µL/hr for 24 hrs post-operatively (Sham Sal, open diamonds, Sham
Glu, open triangles, CLP Sal, closed diamonds, or CLP Glu, closed triangles). Mean arterial blood pressure was averaged over
consecutive periods of 8 hrs, 12 hrs, and 4 hrs. Panel D depicts bacterial colony forming units (CFU) in blood extracted from mice
24 hrs after CLP and subject to post-operative saline or glucose infusion. Statistical differences were determined by Kruskal-Wallis
test with differences between individual means determined by post-hoc Wilcoxon rank-sum tests corrected for multiple comparisons
using the Bonferroni method.
doi: 10.1371/journal.pone.0067716.g006
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patients whereby glucose infusion in the early stages of critical
illness may interact with the ongoing inflammatory response to
drive metabolic decompensation and thus poor outcome.
The FSIVGTT has been used to interrogate dynamic insulin
secretion and glucose disposal in humans and was first
adapted for use in unhandled conscious mice by our group
[20]. The FSIVGTT provides an integrated index of metabolism
that considers both insulin and non-insulin mediated glucose
disposal in the context of insulin secretion from the pancreas,
an important consideration that cannot be modeled using other
standard methods. Using this novel technique, we identified
normal insulin sensitivity in C57BL/6J mice exposed to
endotoxin, consistent with data in healthy humans exposed to
bacterial endotoxin [14,15]. When combined with glucose
infusion, however, endotoxemia dramatically impairs glucose
disposal due to marked insulin resistance. The absence of
changes in non-insulin mediated glucose uptake between the
experimental groups indicates that the impairment in glucose
Figure 7.  Inflammatory cytokine profiles after cecal ligation and puncture.  Mean ± SEM for Interleukin-1β (IL-1β; A),
Interleukin-6 (IL-6; B), Tumor necrosis factor-α (TNF-α; C), and Interleukin-10 (IL-10; D) measured in plasma 18 hrs after either CLP
or sham surgery and infusion with iv saline (Sal) or glucose (Glu) at 100 µL/hr post-operatively. Statistical differences were
determined by two-way ANOVA after log transformation where appropriate with differences between individual means determined
by post-hoc Bonferroni tests.
doi: 10.1371/journal.pone.0067716.g007
Hyperglycemia and Endogenous Insulin in Sepsis
PLOS ONE | www.plosone.org 11 June 2013 | Volume 8 | Issue 6 | e67716
disposal with combined endtoxemia and glucose infusion is
specific to either the interaction of insulin with its receptor
complex on metabolically active tissue or to one or more
components of its well-characterized downstream signal
transduction pathway. Using this model, we are unable to
determine whether the prolonged elevation in circulating insulin
in the endotoxemic mice supplemented with glucose is due to
persistent low-level insulin production or delayed clearance.
However, our data highlight a striking interaction at the level of
the pancreas whereby the insults combine to impede early
phase insulin secretion to a level inappropriate for the degree
of hyperglycemia, a finding we have previously identified as
being critical for survival in endotoxemic mice [12].
A potential limitation of our model is that clinically,
hyperglycemia frequently complicates critical illness and our
endotoxemic mice without exogenous glucose infusion do not
become hyperglycemic, rather they tend to exhibit relative
hypoglycemia. This observation is supported both in the animal
literature [12,16–18] and in several metabolic studies in
endotoxemic humans [13–15]. In order to address this concern
and more closely model human sepsis, we adapted the cecal
ligation and puncture (CLP) model in our double catheterized
mice. Once again, mice became relatively hypoglycemic after
septic insult, consistent with our observations in endotoxemia.
Notably, mice do not eat after the CLP procedure, while they
do take enteral calories after sham surgery, requiring us to
restrict access to chow in sham mice to match calorie intake.
Importantly, profound hyperglycemia ensued following CLP
only in the presence of glucose supplementation, again
suggesting a strong relationship between circulating glucose
and the development of further metabolic decompensation in
sepsis.
While our study does not address mechanism specifically,
the notion that glucose supplementation propagates metabolic
dysfunction in animals experiencing the systemic inflammatory
response syndrome is potentially important as it relates to the
care of critically ill patients. Furthermore, the identification of
pancreatic dysfunction in these animals may have important
translational implications. One attractive potential mechanism
driving this pathophysiologic response relates to inflammatory
cytokine production. For example, IL-1β has been
demonstrated in vitro to suppress pancreatic β-cell function and
to impair insulin signaling in peripheral tissues [24–26].
Similarly, IL-6 and TNF-α have been shown to suppress insulin
signaling and GLUT-4 receptor expression in skeletal muscle,
both of which result in insulin resistance [10,11,27]. Our data
suggest that the administration of glucose early in the evolution
of sepsis can exacerbate the inflammatory cytokine response.
The lack of statistical difference between CLP Glu and CLP Sal
for IL-1β and TNF-α could be due to (1) the time course of the
study as these cytokines are typically produced early following
inflammatory insult, or (2) statistical power as our study was
designed to show metabolic differences between groups rather
than differential cytokine repsonses. Additional mechanisms
contributing to hyperglycemia including alterations in glucose
delivery due to tissue perfusion, increases in counter-regulatory
hormones, changes in lipid profiles, and impaired insulin
signaling remain to be explored in CLP mice receiving glucose
support.
Glucose metabolism may change with time as sepsis
evolves. Our data are limited to the early phase of inflammation
as sepsis develops and cannot be extrapolated to later phases
of the syndrome, which may display very different metabolic
characteristics. Our data are instructive, however, in that they
demonstrate that even low level glucose supplementation early
in the inflammatory response, such as that provided by the
provision of early parenteral nutrition [8] or by maintenance 5%
dextrose infusion in a 70 kg human, may be detrimental,
triggering a cascade of metabolic derangement that may
negatively impact outcomes.
Conclusions
Glucose control and nutritional support in critically ill patients
have been the subject of debate and controversy for the past
decade. While the degree of glucose control and optimal
caloric supplementation remain unclear, it is generally
accepted that hyperglycemia foreshadows poor outcome in
critical illness, and recent evidence suggests that early caloric
supplementation may worsen outcome [8]. The mechanisms
underlying the development of hyperglycemia in sepsis remain
poorly defined, and the protective role of endogenous insulin
production versus the detrimental role of glucose toxicity
continues to be controversial. Our data suggest that a
mechanism exists whereby glucose supplementation early in
the evolution of the systemic inflammatory response syndrome
combines to drive the development of peripheral insulin
resistance and suppresses pancreatic insulin production
thereby amplifying metabolic decompensation and worsening
the degree of hyperglycemia and potentially outcome.
Additional investigation is required to explore the mechanism
by which circulating glucose and systemic inflammation interact
to alter glucose disposal and the pancreatic beta cell response
to hyperglycemia in the setting of sepsis.
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